In addition, these BRCA1-associated breast tumors are usually triple-negative for estrogen receptor α (ER-), progesterone receptor (PR-) and HER2 (HER2-), which makes the development of targeted therapies difficult [21,22,23,24]. Here, ERBB2 is linked to breast neoplasm.